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Extracorporeal membrane oxygenation with nafamostat mesilate as an
anticoagulant for massive pulmonary hemorrhage after living-donor
lobar lung transplantation
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Takeo Tedoriya, MD,c Keiji Goto, MD,d and Nobuyoshi Shimizu, MD,a Okayama, Japan
Living-donor lung lobar transplantation has become anacceptable treatment for selected patients with end-stage pulmonary disease. A few cases of extracorporealmembrane oxygenation (ECMO) for acute severe respi-
ratory failure after lung transplantation have been reported.1-3 We
present our experience with ECMO for acute respiratory failure
resulting from pulmonary hemorrhage after living-donor lobar
lung transplantation.
Clinical Summary
On June 23, 2001, a 27-year-old woman with end-stage primary
pulmonary hypertension underwent bilateral living-donor lobar
transplantation with her father’s right lower lobe and her brother’s
left lower lobe under cardiopulmonary bypass. Postoperative im-
munosuppression was a triple-drug therapy consisting of cyclo-
sporine (INN ciclosporin), azathioprine, and prednisone. Two ep-
isodes of acute rejection required high-dose methylprednisolone
intravenously. On postoperative day 15, severe hypoxia with a
massive hemoptysis developed. The arterial oxygen saturation
(Sao2) was 62% with 100% oxygen. Chest radiography revealed
pulmonary hemorrhages in the right graft (Figure 1). Broncho-
scopic examination demonstrated normal bronchial healing. She
was placed on differential mechanical ventilation with a fraction of
inspired oxygen of 1.0. Positive end-expiratory pressure of the
right lung was 15 cm H2O, and that of the left lung was 5 cm H2O.
At the same time, acute renal failure had developed. She was
therefore treated with ECMO and continuous hemodiafiltration.
Peripheral cannulation was achieved through the left femoral
vein with a 17F venous cannula and through the left femoral artery
with a Dacron polyester fabric graft with a 19F arterial cannula.
The ECMO circuit included a centrifugal pump (CAPIOX EBS;
Terumo Corporation, Tokyo, Japan) and a polypropylene hollow
fiber membrane oxygenator (CAPIOX SX; Terumo Corporation).
All the components of the circuit were treated with heparin coat-
ing. We decided to give extra nafamostat mesilate through contin-
uous infusion of 1.0 to 1.7 mg/(kg  h), keeping the activated
clotting time between 180 and 200 seconds. Immediately after
initiation of ECMO, the Sao2 increased from 62% to 89%, and we
gradually reduced the ECMO flow from 2.5 to 1.0 L/min and the
fraction of inspired oxygen from 1.0 to 0.6, keeping the Sao2
between 95% and 100%. After 43 hours and 23 minutes of ECMO,
the cannulas were removed without any complication, and the
patient was successfully weaned from ECMO. On postoperative
day 36, the patient was weaned from continuous hemodiafiltration,
and she was extubated the next day. On postoperative day 106, the
patient was discharged from the hospital without any respiratory
support.
Discussion
Primary graft failure is a significant complication after lung trans-
plantation. ECMO can be used as a temporary support to allow the
graft function to improve. Fortunately, ECMO after lung trans-
plantation was only needed in 2.7% of the cases, as reported by
Meyers and colleagues.1 Zenati and associates3 reported that 3.6%
of patients required ECMO after lung transplantation. ECMO can
be lifesaving, although mortality remains high. Zenati and associ-
ates3 reported a mortality of 25%. Meyers and colleagues1 reported
a mortality of 42% for 12 patients in whom ECMO had been used
for the same condition.
A pulmonary hemorrhage is a rare but serious complication
after lung transplantation and is associated with serious morbidity.
Pulmonary hemorrhage in lung transplant recipients may be
caused by ischemic and infectious necrosis or by local hemody-
namic factors. Local hemodynamic factors may be especially
related to increased blood flow in the transplanted lung in a
living-donor lung lobar transplantation, because the living-donor
lung graft size is smaller than the bilateral transplant lung graft
size. Therefore the living-donor lung graft vascular bed is smaller
than the bilateral transplant lung graft vascular bed. In this case,
graft function improved during ECMO.
ECMO is administered to patients with respiratory and circu-
latory failure in a state of shock accompanied by risk of bleeding.
Thus the use of heparin is restrained. We used nafamostat mesilate
as an anticoagulant during ECMO, because the patient had acute
respiratory failure caused by pulmonary hemorrhage, accompanied
by high risk of bleeding. Nafamostat mesilate is a synthetic pro-
tease inhibitor that has been found to inhibit various kinds of
enzyme activities for coagulation. There are a few reports of
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ECMO with nafamostat mesilate as an anticoagulant.4,5 Nagaya
and coworkers4 reported that bleeding was well controlled by
nafamostat mesilate administration in 8 of 12 patients who had
some hemorrhagic complications before or during ECMO. Daimon
and associates5 reported ECMO in a patient with acute respiratory
failure caused by pulmonary hemorrhage in a Goodpasture-like
syndrome.
ECMO was successfully used to treat a patient with acute
respiratory failure from pulmonary hemorrhage after living-donor
lobar lung transplantation with nafamostat mesilate as an antico-
agulant. Nafamostat mesilate may be the first choice as an antico-
agulant during ECMO for patients with a high risk of bleeding.
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Figure 1. Chest radiograph showing pulmonary hemorrhage in
right graft.
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